N-linked glycosylation is a predominant post-translational modification of protein in eukaryotes, and its dysregulation is the etiology of several human disorders. The enzyme UDP-N-acetylglucosamine:dolichyl-phosphate N-acetylglucosaminephosphotransferase (GlcNAc-1-P-transferase or GPT) catalyzes the first and committed step of N-linked glycosylation in the endoplasmic reticulum membrane, and it is the target of the natural product tunicamycin. Tunicamycin has potent antibacterial activity, inhibiting the bacterial cell wall synthesis enzyme MraY, but its usefulness as an antibiotic is limited by off-target inhibition of human GPT. Our understanding of how tunicamycin inhibits N-linked glycosylation and efforts to selectively target MraY are hampered by a lack of structural information. Here we present crystal structures of human GPT in complex with tunicamycin. Structural and functional analyses reveal the difference between GPT and MraY in their mechanisms of inhibition by tunicamycin. We demonstrate that this difference could be exploited to design MraY-specific inhibitors as potential antibiotics. NAturE StruCturAL & MoLECuLAr BIoLoGY | VOL 25 | MARCH 2018 | 217-224 | www.nature.com/nsmb
N -linked glycosylation of proteins is one of the most common post-translational modifications in mammals and is involved in many important physiological processes including synaptic transmission, cell adhesion, organellar trafficking, protein folding, and neurodevelopment. The integral membrane enzyme GPT (DPAGT1 in human, ALG7 in yeast) catalyzes the first and committed step of N-linked glycosylation on the cytosolic face of the endoplasmic reticulum (ER) membrane 1 . This reaction involves the transfer of GlcNAc-1-P from UDP-GlcNAc to the carrier lipid dolichyl-phosphate (Dol-P). The dolichyl-diphosphate-N-acetylglucosamine (Dol-PP-GlcNAc) product is further processed by downstream enzymes and flipped into the ER lumen, where processing is completed before the sugars are transferred to the target protein by the oligosaccharyltransferase complex. Recent studies have demonstrated that loss-of-function mutations in DPAGT1 are the etiologies of two types of human neurological diseases, congenital myasthenic syndrome (CMS) 13 and congenital disorder of glycosylation type Ij (CDG-Ij) [2] [3] [4] , and that overexpression of DPAGT1 is a critical contributor to the early development and progression of oral cancer 5, 6 . GPT is a member of the polyprenyl-phosphate-Nacetylhexosamine-1-phosphate-transferase (PNPT) superfamily, which also contains the bacterial paralogs MraY (peptidoglycan synthesis), WecA (lipopolysaccharide and enterobacterial common antigen synthesis), and TarO (teichoic acid synthesis) 7 .
Tunicamycin is a nucleoside-analog inhibitor of many PNPT superfamily enzymes 8, 9 . Tunicamycin was thought of as a transitionstate analog that mimics the substrates UDP-GlcNAc and dolichyl phosphate [10] [11] [12] [13] [14] ( Supplementary Fig. 1 ), but it acts as a high-affinity competitive inhibitor for UDP-GlcNAc in mammalian GPT [15] [16] [17] [18] . Tunicamycin is widely used as a research tool to block N-linked glycosylation or as an ER stress inducer to activate the unfoldedprotein response [19] [20] [21] [22] . Tunicamycin also has potent antibacterial activity, owing to its competitive inhibition of the essential translocase MraY for its natural substrate UDP-MurNAc-pentapeptide 23, 24 . However, tunicamycin has not been used as an antibiotic in the clinic because of its cytotoxicity in mammalian cells arising from its off-target inhibition of GPT 19 . Efforts to develop tunicamycin into an antibiotic are hampered by a dearth of structural information 25 . Of the PNPT superfamily, only the crystal structures of MraY have been published, either from Aquifex aeolicus (MraY AA ), in an Mg 2+bound state 26 and bound to the competitive inhibitor muraymycin D2 (ref. 27 ), or from Clostridium bolteae (MraY CB ), in complex with tunicamycin 28 . MraY contains a highly conserved active site, including ~34 invariant residues, that overlaps with the inhibitor-binding sites; thus, MraY orthologs are known to catalyze the same enzymatic reaction and share natural product inhibitors 23, 26, 27, 29, 30 . The uridine moieties of muraymycin D2 and tunicamycin were bound to the same location in the conserved active site of MraY, which is consistent with the idea that both tunicamycin and muraymycin D2 act as competitive inhibitors to the substrate UDP-MurNAc-pentap eptide 23, 27, 28 (Supplementary Fig. 1 ). Despite progress in our understanding of MraY, a crystal structure of GPT has remained elusive, and many questions remain regarding the mechanism of GPT inhibition by tunicamycin, such as whether tunicamycin inhibits GPT and MraY by the same mechanism. Comparative studies of GPT and MraY are not only crucial to obtaining mechanistic insight into the inhibition of N-linked glycosylation by tunicamycin, but are also important as a platform for the design of antibiotics targeting MraY.
Toward these goals, we solved the crystal structure of human GPT (hGPT) in complex with tunicamycin. Structural analyses performed in parallel with biochemical and enzymatic studies demonstrate that GPT and MraY utilize different quaternary structure organization and mechanisms of inhibition by tunicamycin. Finally, we applied this knowledge to the design of an MraY-specific tunicamycin analog, which would serve as a blueprint for the development of MraY-specific antibiotics.
GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation results
Structure of hGPT bound to tunicamycin. We determined the crystal structures of hGPT in complex with tunicamycin for both the canonical Pro129 variant (UniProt ID Q9H3H5) and a His129 variant (European Nucleotide Archive AAG43168) to 3.10-Å and 2.95-Å resolution, respectively (Table 1) . Both hGPT variants are functionally competent, and they have comparable enzymatic activities ( Supplementary Fig. 2 ). Both models are structurally similar (Cα r.m.s. deviation of ~0.8 Å). We use the canonical Pro129 in all figures, except where noted. The electron density map for the hGPT structure was of excellent quality ( Supplementary Fig. 3 ), allowing unambiguous placement of the entire tunicamycin core as well as the aliphatic tail ( Supplementary Fig. 4 ), which was previously unresolved in the MraY-tunicamycin complex structure 28 .
hGPT crystallized as a homodimer with one tunicamycin molecule bound to the active site of each protomer near the cytosolic side of the ER membrane ( Fig. 1a ). hGPT adopts the canonical PNPT superfamily fold of ten transmembrane helices, with the active site framed on one side by the C-terminal segment of TM9 (TM9b), which is bent outward into the membrane. Notably, hGPT contains a large insertion in loop E between TM9b and TM10, which folds into an extended β α β β motif not seen in MraY ( Supplementary  Fig. 5 ). This β α β β motif protrudes into the cytosol and connects to TM10 via the loop-E helix ( Fig. 1a ). Tunicamycin is bound in an enclosed pocket formed mainly by TM4, TM5, TM6, and TM8 and almost completely covered by cytoplasmic loops A (between TM1 and TM2) and E (between TM9 and TM10) ( Fig. 1a,b ). The aliphatic tail of tunicamycin protrudes into a groove between TM4, TM5, and TM9, which has been suggested to be the binding site for the polyprenyl moiety of undecaprenyl phosphate (C 55 -P) in MraY 26 . Tunicamycin is a high-affinity binder to hGPT, which we characterized by isothermal titration calorimetry (ITC) with a K d of 5.6 ± 1.3 nM in detergent micelles ( Fig. 1c ).
Tunicamycin binding to GPT versus MraY.
To gain further insight into the binding of tunicamycin to hGPT, we next compared the hGPT-tunicamycin complex to the MraY CB -tunicamycin complex 28 ( Fig. 2a ). Tunicamycin is composed of uracil, tunicamine, GlcNAc, and an aliphatic tail 14 ( Supplementary Fig. 1 ). The binding of the uracil, tunicamine, and aliphatic tail moieties of tunicamycin to hGPT is analogous to their binding to MraY CB with noted differences ( Fig. 2b ). The uracil moiety of tunicamycin is stabilized by a conserved π -π stacking interaction with either Phe249 (in hGPT) or Phe228 (in MraY CB ) 28 , which was also observed in the crystal structure of MraY AA in complex with muraymycin D2 (ref. 27 ). This interaction presumably resembles that formed between hGPT or MraY and the uracil moiety of their respective UDP-sugar substrates ( Supplementary Fig. 1 ). The core tunicamine moiety of tunicamycin is stabilized by hydrogen bonds with Asp252 in hGPT and Asp231 in MraY CB . However, the tunicamine moiety forms additional hydrogen bond interactions with Asn119 in hGPT that are not seen in the MraY CB -tunicamycin complex. The amide linkage to the aliphatic tail of tunicamycin is stabilized by an interaction with the invariant Asn185 (Asn172 in MraY CB , but the amide linkage is flipped 180° in MraY CB , possibly owing to the aliphatic tail being unresolved). The tail is further locked into place by Trp122 in hGPT but not in MraY CB (Pro108).
Notably, the interactions formed with the GlcNAc moiety of tunicamycin are considerably different between hGPT and MraY CB (Fig. 2c,d ). Because of the elongated loop E in hGPT, the invariant Arg303 is flipped inward and interacts with the N-acetyl group of the GlcNAc moiety; however, the corresponding residue Arg282 in MraY CB is moved completely away from tunicamycin. The loop-E helix of hGPT does not interact with the GlcNAc moiety of tunicamycin, unlike the loop-E helix of MraY CB (His290 and His291), which is oriented at a 30° angle relative to that in hGPT.
The GlcNAc moiety of tunicamycin has been proposed to mimic the GlcNAc moiety of the endogenous GPT substrate UDP-GlcNAc or the MurNAc moiety in the MraY substrate UDP-MurNAcpentapeptide [11] [12] [13] . These differences in tunicamycin binding could reflect the different substrate specificity of hGPT and MraY.
Another marked difference between the tunicamycin-binding pockets of GPT and MraY is solvent accessibility. The GlcNAc and the uracil moieties of tunicamycin are completely enclosed by loop E and loop A in hGPT, respectively, which was not observed in MraY CB ( Fig. 2e ). Consequently, tunicamycin is sequestered in the active-site pocket of hGPT, but is exposed to the cytosol when bound to the shallow groove of MraY CB .
Distinct dimer interfaces in GPT and MraY. Both GPT and
MraY were previously shown to form a dimer in the membrane 26, 31 . Cooperativity within the GPT dimer was proposed for its function, as a dominant-negative effect was observed by coexpression of the inactive R303K mutant with the wild-type GPT 31 . Strikingly, comparison of the hGPT and MraY structures reveal dramatically different homodimerization interfaces, occurring at opposite sides of the protomer (Fig. 3a) . The GPT dimer is formed by TM2, TM3, TM4, and part of TM1, whereas the MraY dimer is formed by TM10 and parts of TM1 and TM7 (Fig. 3b ). The different dimerization interfaces are supported by sequenceconservation data: the GPT dimerization interface is conserved among GPT sequences but not MraY sequences, and the reverse is true for the MraY dimerization interface ( Fig. 3c ). An unusual membrane-buried disulfide bond is found between Cys106 of each protomer in the canonical hGPT structure, which is absent in the MraY dimer. The conserved nature of this disulfide bond among GPT orthologs provides further evidence that it is the physiological dimerization interface of GPT ( Supplementary Fig. 5 ). We recognized that although the core of the GPT dimerization interface is buried, two hydrophobic fenestrations penetrate the dimer interface from the sides, both containing strong snake-like electron density, which we assigned as a phospholipid tail from the 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) added during protein purification ( Fig. 3b and Supplementary Fig. 6 ). The MraY dimer interface contains a central hydrophobic tunnel separating the TM6 of each protomer, which has been suggested to be occupied by lipid molecules 26 (Fig. 3b ). It is increasingly recognized that interfacial lipids are important for stabilizing membrane protein oligomers 32 . Consistent with this idea, the phosphatidylglyceroldependence of GPT activity has been reported in early studies 33, 34 , suggesting that the observed lipid-dependent regulation of GPT activity might be due to its stabilizing effects on the dimer interface. The opposite dimerization interfaces between GPT and MraY, as well as the resultant difference in lipid accessibility to the interface, suggest that GPT and MraY may potentially be regulated differently by phospholipids.
Distinct roles of Mg 2+ . Mg 2+ is a required cofactor for GPT 35 and MraY 30 enzymatic activity. Extensive studies on MraY catalysis have revealed that three key aspartate residues (Asp116, Asp117, and Asp265 in MraY AA ), conserved throughout the PNPT superfamily, are critical for enzymatic activity 26, 29 . Crystallographic studies unambiguously identified one of the aspartates, Asp265 in MraY AA (Asp231 and Asp252 in MraY CB and hGPT, respectively) as the coordinating residue of the magnesium cofactor ( Fig. 4a ).
It has been suggested that Mg 2+ is required for tunicamycin binding to MraY and GPT, because the tunicamine moiety of tunicamycin is thought to mimic the diphosphate moiety in the transition state of the enzymatic reaction between nucleotide sugar and lipid carrier 10, 12, 13 . However, comparison of the tunicamycinbound hGPT and the Mg 2+ -bound apo MraY AA structures shows that Asp265 (Asp252 in hGPT) coordinates Mg 2+ in MraY AA but interacts directly with tunicamycin in hGPT, suggesting that Mg 2+ and tunicamycin probably compete for binding 26 (Fig. 4a ). If our hypothesis is correct, we predict that Mg 2+ is not required for tunicamycin binding, and we also expect reduced tunicamycin binding with increasing concentrations of Mg 2+ . We performed ITC by titrating tunicamycin into either MraY AA or hGPT in the presence or absence of MgCl 2 (Fig. 4b ). We used MraY AA for our assays because the structure, function, and inhibition of this ortholog have been well studied, and MraY orthologs share common mechanisms of catalysis and inhibition 23, 26, 27, 29, 30 . We found that tunicamycin binds to both MraY AA and hGPT in the absence of Mg 2+ , and the addition of 10 mM MgCl 2 resulted in an eight-fold increase in K d for tunicamycin with MraY AA . Mutating the Mg 2+ -coordinating residue in MraY AA (Asp265) to alanine increased the K d for tunicamycin by over 20-fold. On the contrary, the addition of 10 mM MgCl 2 had no appreciable effect on tunicamycin binding to GPT. Furthermore, mutation of Asp252 to alanine increased K d of tunicamycin by only about three-fold. In summary, our data suggest that the role of Mg 2+ in tunicamycin binding is substantially different in GPT and MraY; whereas Mg 2+ competes with tunicamycin binding to MraY, it has no detectable effect on tunicamycin binding to GPT. These observations are contrary to the previous notion that Mg 2+ is essential for tunicamycin binding to these two enzymes 12, 13 .
Distinct lipid-substrate specificity of GPT and MraY. GPT and MraY utilize different lipid substrates. GPT utilizes dolichyl phosphate, the lipid carrier for eukaryotic N-linked glycosylation, whereas MraY utilizes undecaprenyl phosphate, the lipid carrier for peptidoglycan biosynthesis. A major difference between these two polyprenyl phosphates is the α -isoprene unit closest to the phosphate group: dolichyl phosphate has a saturated bond at this position, and undecaprenyl phosphate has an unsaturated bond (Fig. 4c) . To test the selectivity of GPT and MraY for their respective lipid substrates, hGPT and MraY AA enzymatic reactions were carried out in the presence of either undecaprenyl phosphate (C 55 -P) or C 55 dolichyl phosphate (C 55 -dol-P) ( Fig. 4d ). hGPT exhibits strong selectivity for C 55 -dol-P with nearly no observed activity in the presence of C 55 -P. Conversely, MraY AA shows clear preference for C 55 -P over C 55 -dol-P. This result is consistent with the structural architecture of the hGPT and MraY CB active sites (Fig. 4e ).
Tunicamycin contains a lipid tail that is thought to overlap with the lipid substrate-binding sites in GPT and MraY. In hGPT, the lipid tail of tunicamycin fits snugly into a deep pocket, which is trapped by the conserved Trp122 (Fig. 4e, left) . This highly defined lipid tunnel is likely to be required to constrain dolichyl phosphate, which has higher rotational freedom because of the saturated α -isoprene unit. By contrast, the tunicamycin lipid tailbinding site in MraY is a more shallow and wide groove than the analogous site in GPT (Fig. 4e, right) . The unsaturated α -isoprene unit of undecaprenyl phosphate has a limited degree of rotational freedom, and its assumed geometry probably guides binding to the shallow MraY lipid tail-binding groove. Structural differences between the lipid tail-binding sites in GPT and MraY probably underpin the high selectivity each enzyme exhibits for its respective polyprenyl substrate.
A tunicamycin analog selectively targets MraY over GPT. Efforts to develop tunicamycin as an antibiotic require rational design to eliminate the cytotoxicity arising from its off-target effect on hGPT activity 25, 36 . On the basis of our structural analysis of the tunicamycin-binding site, we designed a tunicamycin analog that replaces the GlcNAc sugar moiety in tunicamycin with a MurNAc sugar (Fig. 5a ), which we synthesized as recently described for the total synthesis of tunicamycin V (Supplementary Note) 37 . The rationale for this chemical modification is that (1) the binding pocket of hGPT formed by loop E tightly packs around the GlcNAc sugar ( Fig. 2e ) and probably cannot accommodate the bulkier MurNAc moiety, and (2) the natural substrate for MraY contains a MurNAc moiety, whereas the natural substrate of hGPT contains a GlcNAc moiety ( Supplementary Fig. 1 ). We observed that the IC 50 of tunicamycin for hGPT is ~9 nM, and that of tunicamycin-MurNAc is ~15 μ M, resulting in an ~1,000fold decrease in inhibition of hGPT by this simple modification of tunicamycin ( Fig. 5b) . By contrast, the activity of MraY AA is similarly inhibited by both tunicamycin and tunicamycin-MurNAc (Fig. 5b) . This observation is consistent with the crystal structure of MraY CB bound to tunicamycin, which demonstrates that the binding site of the tunicamycin GlcNAc moiety is wider than that of hGPT and is therefore more likely to accommodate the larger MurNAc moiety ( Fig. 2e ). Therefore, we showed proof of principle to selectively target tunicamycin toward MraY over GPT at the protein level. Further investigation is required to evaluate the in vivo activity and toxicity of such analogs.
Discussion
Our structural and functional studies of hGPT provide the framework to elucidate the molecular basis of mutations that cause CDG-Ij and CMS13 ( Supplementary Fig. 7) . Intriguingly, distinct groups of mutations within DPAGT1 are responsible for either CDG-Ij or CMS13, and they are spread over hGPT rather than localized around the active site of hGPT ( Supplementary Fig. 7) . Systematic enzymatic, structural, and cellular studies are required to understand the effects of disease mutations on hGPT and N-linked glycosylation.
GPT and MraY have drastically different dimer organization. It is unusual to have distinct dimerization organization among paralogs for enzymes. What is the possible reason for distinct dimerization of GPT compared to MraY? Although the cooperativity of the GPT dimer and the importance of phosphatidyglycerol to GPT function have been reported, no studies were reported for the cooperativity of the MraY dimer. We observed that the two active sites are closer together in the GPT dimer than in the MraY dimer. In the GPT dimer, part of TM1 and loop A is closer to the symmetric axis ( Fig. 1) , potentially enabling communication between the two active sites within the dimer, which is not present in the MraY dimer. Therefore, we speculate that the distinct dimerization of GPT enables cooperativity, which adds another layer of complexity to the regulation of this eukaryotic system.
We showed that the mechanisms of tunicamycin binding to MraY and GPT are different in many respects. First, we found that the role of Mg 2+ is different in tunicamycin inhibition of GPT and MraY. Potential reasons for this difference include: (1) GPT forms Labeled residues in magenta are known to be critical for MraY AA activity, and Asp265 coordinates the magnesium cofactor (magenta sphere). b, Fold increase in K d of tunicamycin with either hGPT or MraY as measured by ITC. The K d of tunicamycin for hGPT without added MgCl 2 is 5.6 ± 1.3 nM (mean ± s.e.m. of three technical replicates). The K d of tunicamycin for MraY AA without added MgCl 2 is 37 ± 1 nM (mean ± s.e.m. of three technical replicates). c, Chemical structures of dolichyl phosphate and undecaprenyl phosphate. d, TLC-based specific activity assay for hGPT and MraY AA in the presence of either dolichyl phosphate (C 55 -dol-P) or undecaprenyl phosphate (C 55 -P). hGPT is selective for the saturated α -isoprenyl position in its substrate dolichyl phosphate, whereas MraY is selective for the unsaturated α -isoprenyl position in its substrate undecaprenyl-phosphate. Specific-activity measurements were normalized relative to the C 55 -Dol-P condition for hGPT and to the C 55 -P condition for MraY. Data are shown as mean ± s.e.m. of three technical replicates. Significance was determined with P < 0.001, two-tailed Student's t test. e, Cytoplasmic view of the tunicamycin lipid tail-binding sites in hGPT and MraY CB . In GPT, the aliphatic tail of tunicamycin packs against the conserved Trp122, which forms a lipid-binding tunnel. By contrast, the corresponding residue in MraY CB (Pro108) is unable to lock the lipid tail into place, leaving the hydrophobic groove exposed. Source data for b and d are available online. several additional interactions with tunicamycin, thereby making it less readily displaced by Mg 2+ , and (2) the Mg 2+ -binding site in GPT is different to that in MraY. Second, we found that the active-site shape and solvent accessibility is considerably different between GPT and MraY. Difference in the active-site shape could reflect the substantial difference in size between the GPT substrate UDP-GlcNAc (~600 Da) and the MraY substrate UDP-MurNAcpentapeptide (~1,200 Da) ( Supplementary Fig. 1) ; the former could be easily captured in an enclosed pocket, whereas the latter would require an exposed groove for binding. Third, the lipid-substrate specificity is distinct in GPT and MraY, which is further supported by structural differences in the lipid-binding site of each enzyme. We exploited one of these distinctions to design a tunicamycin analog with biased specificity toward MraY at the enzyme level. Our proof-of-principle studies with tunicamycin-MurNAc demonstrate that developing MraY-specific tunicamycin analogs is possible. In principle, we believe many of the features that distinguish MraY and GPT could be used for the development of MraY-specific tunicamycin analogs, such as the lipid tail portion of tunicamycin, which can be modified to reduce affinity for GPT.
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in Supplementary Note). In brief, the analog was synthesized by assemblage of a trichloroacetimidate of MurNAc N-methylamide derivative S5 as a glycosyl donor and a suitably protected tunicaminyluracil S6 as a glycosyl acceptor 37 . Namely, treatment of S5 and S6 with TfOH in Et 2 O at 0 °C provided the desired 11′ -β -1′ ′ -α -glycoside S7 in 69% yield in a highly stereoselective manner. Transformation of the azide group, deprotection of the phthaloyl group at the GalNAc moiety, and installation of the fatty acyl group gave S10. Finally, global deprotection of five acid labile protecting groups by BCl 3 resulted in clean conversion to afford tunicamycin-MurNAc. For functional studies (ITC and enzymatic assays), sample size represents the number of measurements. Sample size was chosen based on pilot experiments and on requirements to reach statistical significance.
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